BALSM MEDICAL

Balsm Alofoq Medical Company

9620StocksTadawulHealthcare

Financials

	CurrentMar 10, 2026	2025Dec 31, 2025	2024Dec 31, 2024	2023Dec 31, 2023	2022Dec 31, 2022
Market & Price
Market Capitalization	57.50M	68.15M	92.50M	—	—
Market Cap Growth	-38.7%	-26.3%	—	—	—
Enterprise Value	48.17M	51.75M	89.18M	—	—
Last Close Price	23.00	27.26	37.00	—	—
Valuation Multiples
PE Ratio	29.23	34.64	19.35	—	—
PS Ratio	2.82	3.35	4.66	—	—
PB Ratio	1.86	2.21	3.20	—	—
P/TBV Ratio	1.86	2.21	3.20	—	—
P/FCF Ratio	—	—	17.55	—	—
P/OCF Ratio	—	—	16.87	—	—
EV/Sales Ratio	2.36	2.54	4.49	—	—
EV/EBITDA Ratio	13.07	15.11	14.75	—	—
EV/EBIT Ratio	19.25	20.68	17.43	—	—
EV/FCF Ratio	-6.79	—	16.92	—	—
Leverage & Capital
Debt / Equity Ratio	0.05	0.05	0.06	0.13	0.36
Debt / EBITDA Ratio	0.41	0.41	0.29	0.35	0.51
Debt / FCF Ratio	—	—	0.34	—	0.58
Net Debt / Equity Ratio	-0.30	-0.30	-0.57	-0.12	-0.42
Net Debt / EBITDA Ratio	-2.72	-2.72	-2.72	-0.34	-0.67
Net Debt / FCF Ratio	1.32	1.32	-3.12	1.01	-0.69
Efficiency & Liquidity
Asset Turnover	0.59	0.59	0.77	1.08	—
Inventory Turnover	4.77	4.77	7.19	9.06	—
Quick Ratio	5.80	5.80	11.51	2.64	1.39
Current Ratio	10.26	10.26	12.94	3.81	1.69
Returns & Yields
Return on Equity (ROE)	+6.6%	+6.6%	+22.1%	+38.3%	—
Return on Assets (ROA)	+4.5%	+4.5%	+12.3%	+16.2%	—
Return on Invested Capital (ROIC)	+9.3%	+11.8%	+38.6%	+50.3%	+84.9%
Return on Capital Employed (ROCE)	+7.4%	+7.4%	+16.2%	+25.4%	+35.5%
Earnings Yield	+3.4%	+2.9%	+5.2%	—	—
FCF Yield	-12.3%	-10.4%	+5.7%	—	—
Dividend Yield	—	—	+4.1%	—	—
Payout Ratio	—	—	+62.8%	+23.1%	—
Buyback Yield / Dilution	—	—	-69.4%	—	—
Total Shareholder Return	—	—	-65.4%	—	—

	CurrentMar 10, 2026	2025Dec 31, 2025	2024Dec 31, 2024	2023Dec 31, 2023	2022Dec 31, 2022
Market & Price
Market Capitalization	57.50M	68.15M	92.50M	—	—
Market Cap Growth	-38.7%	-26.3%	—	—	—
Enterprise Value	48.17M	51.75M	89.18M	—	—
Last Close Price	23.00	27.26	37.00	—	—
Valuation Multiples
PE Ratio	29.23	34.64	19.35	—	—
PS Ratio	2.82	3.35	4.66	—	—
PB Ratio	1.86	2.21	3.20	—	—
P/TBV Ratio	1.86	2.21	3.20	—	—
P/FCF Ratio	—	—	17.55	—	—
P/OCF Ratio	—	—	16.87	—	—
EV/Sales Ratio	2.36	2.54	4.49	—	—
EV/EBITDA Ratio	13.07	15.11	14.75	—	—
EV/EBIT Ratio	19.25	20.68	17.43	—	—
EV/FCF Ratio	-6.79	—	16.92	—	—
Leverage & Capital
Debt / Equity Ratio	0.05	0.05	0.06	0.13	0.36
Debt / EBITDA Ratio	0.41	0.41	0.29	0.35	0.51
Debt / FCF Ratio	—	—	0.34	—	0.58
Net Debt / Equity Ratio	-0.30	-0.30	-0.57	-0.12	-0.42
Net Debt / EBITDA Ratio	-2.72	-2.72	-2.72	-0.34	-0.67
Net Debt / FCF Ratio	1.32	1.32	-3.12	1.01	-0.69
Efficiency & Liquidity
Asset Turnover	0.59	0.59	0.77	1.08	—
Inventory Turnover	4.77	4.77	7.19	9.06	—
Quick Ratio	5.80	5.80	11.51	2.64	1.39
Current Ratio	10.26	10.26	12.94	3.81	1.69
Returns & Yields
Return on Equity (ROE)	+6.6%	+6.6%	+22.1%	+38.3%	—
Return on Assets (ROA)	+4.5%	+4.5%	+12.3%	+16.2%	—
Return on Invested Capital (ROIC)	+9.3%	+11.8%	+38.6%	+50.3%	+84.9%
Return on Capital Employed (ROCE)	+7.4%	+7.4%	+16.2%	+25.4%	+35.5%
Earnings Yield	+3.4%	+2.9%	+5.2%	—	—
FCF Yield	-12.3%	-10.4%	+5.7%	—	—
Dividend Yield	—	—	+4.1%	—	—
Payout Ratio	—	—	+62.8%	+23.1%	—
Buyback Yield / Dilution	—	—	-69.4%	—	—
Total Shareholder Return	—	—	-65.4%	—	—